What is Elevian?
Elevian is a biotech innovator established in 2017 and headquartered in Allston, Massachusetts. The company is dedicated to the development of medicines designed to restore youthful regenerative capacity, offering a potential pathway to treat and prevent a variety of age-related diseases. Its scientific approach targets fundamental mechanisms of aging, positioning it at the forefront of longevity research and therapeutic development. The company's work signifies a growing trend in the pharmaceutical industry towards addressing aging as a treatable condition.
How much funding has Elevian raised?
Elevian has raised a total of $55M across 2 funding rounds:
Angel/Seed
$15M
Series A
$40M
Angel/Seed (2020): $15M with participation from Western Technology Investment, Prime Movers Lab, Kizoo Ventures, Lauder Partners, For Good Ventures, BOLD Capital Partners, Longevity Fund companies, and SavEarth Fund
Series A (2021): $40M led by John A Kuelbs Family Office, Leslie Ventures, BOLD Capital Group, and Prime Movers Lab
Key Investors in Elevian
BOLD Capital Group
BOLD Capital Group is a venture capital firm specializing in early-stage technology platforms, with a focus on healthcare and other innovative sectors. They provide investment and advisory services to help companies grow and navigate capital needs.
Prime Movers Lab
Prime Movers Lab is a venture capital firm that invests in breakthrough scientific startups aiming to transform industries and improve lives. They support founders with innovative ideas and a growth mentality.
Longevity Fund companies
The Longevity Fund is a venture capital firm focused on funding companies developing drugs for age-related diseases and longevity, aiming to bring longevity drugs into mainstream medicine.
What's next for Elevian?
With the recent infusion of major strategic capital, Elevian is poised for accelerated growth and the advancement of its therapeutic pipeline. This significant investment, part of its overall $55M in funding, will likely fuel further research and development, clinical trials, and potential expansion of its operational capabilities. The company's focus on age-related diseases and regenerative medicine places it in a high-growth sector, attracting substantial backing from investors keen on transformative healthcare solutions. Future developments are expected to center on progressing its lead candidates through regulatory pathways and expanding its portfolio of treatments.
See full Elevian company page
